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Abstract: Soft tissue augmentation with temporary dermal ﬁ  llers is a continuously growing ﬁ  eld, 
supported by the ongoing development and advances in technology and biocompatibility of the 
products marketed. The longer lasting, less immunogenic and thus more convenient hyaluronic 
acid (HA) ﬁ  llers are encompassing by far the biggest share of the temporary dermal ﬁ  ller market. 
Since the approval of the ﬁ  rst HA ﬁ  ller, Restylane®, there are at least 10 HA ﬁ  llers that have 
been approved by the FDA. Not all of the approved HA ﬁ  llers are available on the market, 
and many more are coming. The Juvéderm™ product line (Allergan, Irvine, CA), consisting 
of Juvéderm™ Plus and Juvéderm™ Ultra Plus, was approved by the FDA in 2006. Juvéderm™ 
is a bacterium-derived nonanimal stabilized HA. Juvéderm™ Ultra and Ultra Plus are smooth, 
malleable gels with a homologous consistency that use a new technology called “Hylacross™ 
technology”. They have a high concentration of cross-linked HAs, which accounts for its 
longevity. Juvéderm™ Ultra Plus is used for volumizing and correcting deeper folds, whereas 
Juvéderm™ Ultra is best for contouring and volumizing medium depth facial wrinkles and lip 
augmentation. Various studies have shown the superiority of the HA ﬁ  ller products compared 
with collagen ﬁ  llers for duration, volume needed, and patient satisfaction. Restylane®, Perlane®, 
and Juvéderm™ are currently the most popular dermal ﬁ  llers used in the United States.
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Dermal ﬁ  llers have become an integral part of any aesthetic physician’s intervention. The 
growing importance of the temporary dermal ﬁ  ller industry is reﬂ  ected by the increasing 
growth in demand during the past years and a multitude of new products, which have 
come to market. According to the American Academy of Aesthetic Plastic Surgeons, 
1,448,716 people received hyaluronic acid (HA) injections by plastic surgeons in 2007. 
This number does not, however, reﬂ  ect all the procedures performed, as it does not 
include the procedures performed by dermatologists or other physicians.
The ﬁ  rst dermal ﬁ  llers used in the 1980s were animal-derived collagen ﬁ  llers 
(Zyplast® and Zyderm®; Allergan, formerly Inamed). However, the need for products 
with longer clinical duration and no requirements for prior skin allergy testing lead to 
the development of the HA ﬁ  llers. Of the two biologic ﬁ  llers currently used – collagen 
and HAs – HAs have become the new gold standard, and have almost replaced col-
lagen ﬁ  llers (Cosmetic Surgery National Data Bank Statistics 2005). This is explained 
by the advantages of HAs over collagen, such as its longer duration (6–12 months 
compared with 2–4 months), no request for skin testing, fewer allergic side effects, 
and better pliability.
A third group of dermal ﬁ  llers currently used are synthetic ﬁ  llers, such as Sculptra® 
(Dermik Laboratories, Sanoﬁ  -Aventis, Bridgewater, NJ), Radiesse® (BioForm Medical, 
San Mateo, CA), and Arteﬁ  ll® (Artes Medical, Inc., San Diego, CA).Clinical Interventions in Aging 2008:3(4) 630
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HA or hyaluronan is a naturally occurring linear 
polysaccharide (Figure 1). It can be found in skin, connec-
tive, epithelial, and neural tissues. It is ubiquitous across 
all species and does not require skin allergy testing prior 
to injection, which makes it very convenient for daily use. 
This glycosaminoglycan has the ability to bind 1,000 times 
its volume in water, which makes it the perfect substance for 
adding volume to the skin. In humans, the amount of naturally 
occurring HA in the skin decreases with age, which plays an 
important role in the development of the aging features and 
wrinkle formation, resulting in decreased tissue elasticity and 
hydration. Unmodiﬁ  ed, natural HA has a half-life of approxi-
mately 24 hours before it is enzymatically broken down and 
metabolized in the liver into byproducts, water and carbon 
dioxide (Duranti et al 1998). In the skin, HA is broken down 
by hyaluronidase and by free radicals. Supplementation with 
oral antioxidants theoretically will increase the duration of 
HA ﬁ  llers, but this has not been proven. The naturally occur-
ring break down of HA by hyaluronidase depicts an important 
feature of the HA ﬁ  llers as well as a major advantage over 
the collagen ﬁ  llers, namely, rarely occurring areas of excess 
fullness, too superﬁ  cial placement of the ﬁ  ller, or overcor-
rection can easily be dissolved or improved by intralesional 
injection of hylauronidase.
Features that differentiate the various HA ﬁ  llers are par-
ticle size, the type of crosslinking agent used, the degree of 
crosslinking, the percentage of cross-linked HA, the amount 
of free (unmodiﬁ  ed) HA present, and G´ (elastic modulus). 
All these physical and chemical attributes will inﬂ  uence the 
clinical characteristics of each ﬁ  ller, such as clinical indica-
tion, ease of injection, degree of tissue ﬁ  lling, longevity, 
clinical appearance, and side effects.
Currently 6 temporary HA ﬁ  llers are FDA approved and 
on the market in the US: Restylane® (Medicis, Scottsdale, AZ), 
Perlane® (Medicis, Scottsdale, AZ), Prevelle Silk® (Mentor 
Corp., Santa Barbara, CA), Hylaform Plus® (Allergan, 
Irvine, CA), Anika® (Anika Therapeutics, Inc., MA), and 
Juvéderm™ (Allergan, Inc., Irvine, CA) (Table 1). Hylaform® 
and Captique® are no longer on the market in the US.
Juvéderm™ (Allergan, Inc., Irvine, CA), which is also 
known as Hydraﬁ  ll, was approved by the FDA in June 2006 
for the correction of moderate to severe facial wrinkles and 
folds. Juvéderm™ ﬁ  ller agents have been on the market in 
European countries and Canada since 2003 (marketed as 
Juvéderm™ by the Corneal Group and by Allergan, formerly 
Inamed, and in some countries as Hydra Fill® by Allergan, 
formerly Inamed). The Juvéderm™ line comprises various 
products, such as Juvéderm™ 18, Juvéderm™ 24, Juvéderm™ 
24 HV, Juvéderm™ 30, and Juvéderm™ 30 HV, of which only 
Juvéderm™ 24 HV (also known as Juvéderm™ Ultra) and 
Juvéderm™ 30 HV (also known as Juvéderm™ Ultra Plus) 
are available on the US market. The various products in the 
line differ in the concentration of HA as well as the amount 
and regularity of crosslinking.
Particle size and sizing technology
Juvéderm™ is derived from Streptococcus equi and manu-
factured by a bacterial fermentation process. Juvéderm™ is 
produced by a proprietary manufacturing process referred 
to as “Hylacross technology”, which refers to the fact that 
Juvéderm is not “sized” in contrast to the other HA ﬁ  llers 
(Prevelle Silk®, Restylane®, Perlane®) which use sizing 
technology. “Sizing” is the process by which crosslinked 
HA is pushed through a specially sized screen and broken 
into pieces. The medium size pieces of HA are made into 
Restylane® while the larger ones are made into Perlane®. It is 
unknown what effect the sizing technology or the Hylacross 
technology have on a ﬁ  ller’s performance, or if they offer 
any beneﬁ  t in the efﬁ  cacy of the product. Many claims 
about the beneﬁ  ts of Hylacross technology have been made 
without scientiﬁ  c substantiation. For example, Smith (2007) 
noted a difference of the homologous Juvéderm™ gel ﬁ  llers 
compared to ﬁ  llers with gel particle suspensions, mentioned 
in his publication on the practical use of Juvéderm™. He 
claimed that after injection, the Juvéderm™ ﬁ  ller remained in 
the area where it was injected because of its cohesive nature 
and high viscosity, and did not ﬂ  ow away from the injection 
point. Also, in his opinion, Juvéderm ﬁ  lls more precisely and 
more efﬁ  ciently. He stated that gel-particle ﬁ  llers in contrast 
seem to ﬂ  ow away from the injection point, causing ﬁ  lling 
of unintended areas and waste of product. It is important to 
realize that this is one person’s opinion and has not been sub-
stantiated by scientiﬁ  c research. To the authors’ knowledge, 
no studies have scientiﬁ  cally characterized the diffusion and 
spread of the various HA ﬁ  llers.
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HA concentration
The amount of HA in a product may contribute to its stiffness 
and longevity. Theoretically, the higher the amount of HA 
in the product, the stiffer it is and the longer it will last. 
However, not all of the HA in the product is crosslinked so 
one must take into account the overall percentage of cross-
linking (how much of the HA is crosslinked) and the degree 
of crosslinking (is the HA molecule completely or partially 
crosslinked). Often, uncrosslinked HA is added to a ﬁ  ller 
product to increase its ease of injection as it functions as a 
lubricant. Both Juvéderm™ Ultra and Ultra Plus consist of 
24 mg/mL of HA. Juvéderm™ Ultra is 9% crosslinked while 
Juvéderm™ Ultra Plus is 11% crosslinked (Table 2).
Type of crosslinking agent used
The crosslinking agent used in Juvéderm™ is 1,4-butanediol 
diglycidyl ether (BDDE). Other ﬁ  llers are cross-linked 
with different crosslinking agents, such as divinyl sulphone 
(DVS) for Prevelle®, Captique®, and Hylaform®. Puragen® 
is cross-linked with 2, 7, 8-diepoxyoctane (DEO), which 
forms both ether and ester crosslinks. Crosslinking quality 
has to be in the right balance to maintain both duration and 
the biocompatibility of the HA ﬁ  ller. Each crosslinking agent 
has characteristics that affect the performance of the ﬁ  ller.
Elastic modules
The stiffness or G´ (pronounced G prime) of a product is one 
of the most important considerations. G´ is a measurement of 
gel hardness. It is obtained when a gel is placed on a plate. 
A second plate is placed over the gel and a lateral force is 
applied. The measurement of resistance to deformation is 
known as the elastic modulus or the G´. Together with the 
cohesivity of the product, G´ values could be used to deter-
mine the appropriate placement of an HA dermal ﬁ  ller. For 
example more robust products (higher G´ values and higher 
cohesivities) such as Juvéderm™ Ultra Plus and Perlane®, 
should be used in deeper lines, such as nasolabial folds and 
marionette lines, as well as to lift the lateral brow, to correct 
the nasal bridge, to give the ear lobe youthful volume, to evert 
the nipples, and to raise the nasal tip. More ﬂ  uid products 
such as Juvéderm™ Ultra and Restylane® are more suited to 
be used over large areas such as the cheekbones and cheeks. 
Low G´ products such as Hylaform® and Prevelle Silk® are 
necessary in areas that require a softer agent, such as the 
body of the lip or the tear trough. As new products reach the 
market, knowing the G´ will help practitioners match ﬁ  llers 
with indications.
Recommended injection sites
In contrast to Juvéderm™ Ultra, Juvéderm™ Ultra Plus has 
a higher proportion (11%) of crosslinked HA, which makes 
Ultra Plus more viscous. Consequently, Ultra Plus is more 
suitable for adding volume and correcting the deeper facial 
grooves and furrows, whereas Juvéderm™ Ultra is best suited 
for contouring and volumizing facial wrinkles and folds 
(Figures 2 and 3) (FDA 2006). Juvéderm™ Ultra and Ultra 
Plus can be grouped in the medium range of product stiff-
ness, which makes them suitable for the use in any wrinkles, 
moderate or deep, as well as scar correction. Both Juvéderm™ 
products contain unmodiﬁ  ed or uncross-linked, free HA. 
Unmodiﬁ  ed HA is included as a lubricant to help decrease 
extrusion force and make injection easier. Juvéderm™ Ultra 
is injected into the mid-dermis via 30-gauge needle while 
Juvéderm™ Ultra Plus is implanted deeper via a 27-gauge 
needle. It is important to tightly attach the needles to the 
Luer-lock syringe to prevent detachment during injections. 
Various techniques of injection can be used with Juvéderm™, 
including serial puncture and tunneling. As Juvéderm™ is not 
Table 1 Hyaluronic acid (HA) ﬁ  llers: crosslinking agents and concentration of HA
Product Captique Hylaform Juvéderm Ultra 
and Ultra Plus
Puragen Prevelle Restylane 
and Perlane
Crosslinking agent DVS DVS BDDE DEO DVS BDDE
Concentration 4.5–6.5 mg/mL 4.5–6.5 mg/mL 24 mg/mL 20 mg/mL 4.5–6.5 mg/mL 20 mg/mL
Abbreviations: BDDE , 1,4-butanediol diglycidyl ether; DVS, divinyl sulphone; DEO, 2, 7, 8-diepoxyoctane.
Table 2 Percentage crosslinking in Juvéderm™ products
Juvéderm 30 Juvéderm 24 HV (Ultra) Juvéderm 30 HV (Ultra Plus)
Concentration 24 mg/g 24 mg/g 24 mg/g
Crosslinking rate 9% 9% 11%Clinical Interventions in Aging 2008:3(4) 632
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completely hydrated with water in the syringe, and HA is 
well known to be able to bind 1,000 times its weight in water, 
Juvéderm™ will absorb water after injections and thus slightly 
expand within 24 hours after correction. The patients can thus 
be informed, that the effect will be “even better” 24 hours 
after the injection. However, it is important to consider this 
feature in clinical practice, especially when injecting the 
body of the lips, therefore one should always undercorrect 
to allow for expansion. Restylane® and Puragen® are also 
not completely hydrated in the syringe, whereas Captique®, 
Hylaform®, and Prevelle® are completely hydrated and will 
not expand after injection.
The longevity of Juvéderm™ Ultra is about 6–9 months 
and Ultra Plus may last up to 12 months, which is similar 
to Restylane® and Perlane®. Captique® and Prevelle Silk® 
are thought to last 4–6 months and the duration of Puragen® 
is unknown at the time of publication of this article. Both 
Juvéderm™ products are packaged in 0.8-mL syringes as a 
clear gel and are stored at room temperature with a shelf-life 
of 24 months. The adverse-event proﬁ  le of Juvéderm™ is 
mild and transient. As with all HA products, Juvéderm™ can 
cause erythema, swelling, and bruising after implantation. As 
Juvéderm™ Ultra and Ultra Plus lack an anesthetic, patients do 
feel pain during injection. Therefore, a topical anesthetic or a 
nerve block can be used to minimize discomfort.
Both Juvéderm™ Ultra and Ultra Plus have been approved 
for use in the nasolabial folds. In the authors’ experience, 
both products may also be used off-label for lip augmenta-
tion, for the correction of marionette folds, prejugal sulci, and 
as volume ﬁ  llers for atrophy and acne scars. Furthermore, 
Juvéderm™ can be placed in the tear trough area, but extra 
care is necessary, due to the proximity to the eye with the 
risk of the needle popping off, thus one should inject very 
slowly with only moderate extrusion force. The needle is 
more likely to pop off when the syringe is almost empty so 
inject the tear trough area with a new syringe and save the 
last part of the syringe for less dangerous areas such as the 
nasolabial folds. Too superﬁ  cial injections of Juvéderm™ can 
result in a bluish hue. Juvéderm™ Ultra can easily be placed 
in the vermillion border or the body of the lip. Again, one 
should be cautious as not to over-inject the vermillion border 
due to postponed expansion of the product.
As Juvéderm™ has been on the US marked only since 
late 2006, only a few publications have assessed the vari-
ous characteristics of the Juvéderm™ products. These are 
reviewed below.
Review of publications
In the pivotal trial that led to FDA approval of Juvéderm™, 
Baumann et al (2007) compared the safety and effective-
ness of 3 types of smooth-gel HA dermal ﬁ  llers vs cross-
linked collagen in the treatment of NLF in 439 subjects in 
a multicenter, double-masked, randomized, within-subject 
study. The subjects randomly received one of three types of 
smooth-gel HA dermal ﬁ  ller in one NLF and cross-linked 
bovine collagen in the other. The three different smooth-gel 
HAs used were J30 (Juvéderm™ 30), 24 HV (Juvéderm™ 
Ultra), or 30 HV (Juvéderm™ Ultra Plus), of which only the 
latter two are currently marketed in the US. The cross-linked 
bovine collagen ﬁ  ller used was Zyplast® (Allergan, formerly 
Inamed). The NLFs were to be ﬁ  lled to full correction (100% 
of the defect), and not overcorrected, and a maximum of 
3 treatments – ﬁ  rst treatment and up to 2 touch-ups at 
roughly 2-week intervals – were allowed to achieve optimal 
correction. NLF severity was assessed using the 5-point Wrinkle 
Assessment Scale (WAS), with 0 = none (no wrinkle); 
1 = mild (shallow, just perceptible wrinkle); 2 = moderate 
Figure 2 Before Juvedérm™ to the Marionette lines.
Figure 3 24 hours after Juvedérm™ Ultra to right Marionette line.Clinical Interventions in Aging 2008:3(4) 633
HA gel for facial wrinkles and folds
(moderately deep wrinkle); 3 = severe (deep wrinkle, well-
deﬁ  ned edges but not overlapping); 4 = extreme (very deep 
wrinkle, redundant fold with overlapping skin). The results 
showed that all three dermal ﬁ  llers proved longer-lasting 
clinical corrections than bovine collagen. Twenty-four weeks 
after the last treatment, 90% of subjects treated with 30 HV 
(Juvéderm™ Ultra Plus) dermal ﬁ  ller retained a clinically 
signiﬁ  cant improvement, 88% treated with 24 HV (Juvé-
derm™ Ultra) and 81% with J30 dermal ﬁ  ller. The bovine 
collagen–treated NLFs showed clearly shorter longevity 
with lasting improvement after 24 weeks ranging from 36% 
to 45%. In addition to its superior longevity, the injection 
volume for HA dermal ﬁ  llers proved to be lower (median, 
1.6 mL) compared with bovine collagen (median, 2.0 mL), 
representing an additional important advantage for the patient 
in treatment costs and comfort. The only treatment-related 
adverse events observed were localized site reactions in the 
area of injection, which were mild to moderate in severity 
and did not differ between any ﬁ  ller type. In decreasing 
percentage those were injection site induration, erythema, 
edema, pain, nodule formation, bruising, discoloration, and 
pruritus; they lasted no more than 7 days. The preferred ﬁ  ller 
by the patients used was 24 HV (Juvéderm™ Ultra) with 88%, 
followed by 84% for 30 HV (Juvéderm™ Ultra Plus) and 78% 
for J30; the majority of subjects preferred HA ﬁ  llers to the 
collagen ﬁ  llers.
In an almost identical study design (Pinsky et al 2007), 
the safety and effectiveness of Juvéderm™ dermal ﬁ  llers 
compared to Zyplast® bovine collagen for the correction 
of nasolabial folds (NLFs) was assessed in a multicenter, 
double-blind, randomized, within-subject controlled trial. 
292 subjects were randomly treated with Juvéderm™ Ultra 
or Juvéderm™ Ultra Plus in one NLF and Zyplast® bovine 
collagen in the other NLF. The treating investigators were 
instructed to ﬁ  ll each NLF to full correction (100% of the 
defect), but not to overcorrect. A maximum of 3 treatments 
– ﬁ  rst treatment and up to 2 touch-ups at roughly 2-week 
intervals – were allowed to achieve optimal correction. 
An average injection volume of 1.5 mL (2 syringes) of 
Juvéderm™ dermal ﬁ  ller was used for initial treatment and 
0.7 mL (1 syringe) for repeat treatment. NLF severity was 
assessed using the 5-point Wrinkle Assessment Scale (WAS), 
and a validated photographic guide. After 6 month subjects 
showed a clinically signiﬁ  cant mean level of improvement 
for the NLFs treated with Juvéderm™ Ultra or Juvéderm™ 
Ultra Plus, but not for NLFs treated with Zyplast®, supporting 
the above stated ﬁ  ndings by showing a longer longevity for 
Juvéderm™ Ultra and Ultra Plus than for Zyplast®. The mean 
level of improvement was still clinically signiﬁ  cant for 
subjects who returned for a follow-up treatment beyond 
9 months, with the proportion of NLFs still showing clinically 
signiﬁ  cant improvement in 75% with Juvéderm™ Ultra and 
81% with Juvéderm™ Ultra Plus. Juvéderm™ Ultra Plus was 
shown to last even 12 months or longer. Again, the frequency 
and severity of treatment site reactions (eg, erythema, indura-
tion, pain, edema, nodule formation, bruising, pruritus, and 
discoloration) were mild or moderate and were similar for all 
ﬁ  llers. The authors concluded, that due to its superior longev-
ity, individuals treated with these Juvéderm™ dermal ﬁ  llers 
may require to repeat treatments less frequently than those 
treated with bovine collagen ﬁ  llers, and that less product will 
be needed at repeat treatments.
The results of the above mentioned studies are supported 
by a recent study by Lupo et al which compared Juvéderm™ 
Ultra Plus HA ﬁ  ller with Zyplast® bovine collagen in a mul-
ticenter, double-blind, randomized, within-subject, controlled 
study (Lupo et al 2008). In a split face mode, severe NLFs 
of 87 subjects were treated, one side with Juvéderm™ Ultra 
Plus and the other side with Zyplast®. In the study popula-
tion all Fitzpatrick skin types were represented, 36% having 
darker skin types (Fitzpatrick types IV through VI). Up to 
two touch-up treatments were allowed at 2-week intervals. 
Effectiveness was assessed using the validated, static, 5-point 
Wrinkle Assessment Scale (WAS) with a photographic guide. 
The Juvéderm™ Ultra Plus ﬁ  ller showed signiﬁ  cantly better 
NLF severity scores compared to Zyplast® at each follow-up 
time point from 4 to 24 weeks. At 24-week follow-up clini-
cally signiﬁ  cant correction of NLF treated with Juvéderm™ 
were shown in 96% compared with 41% Zyderm®. The 
clinical correction with Juvéderm™ Ultra Plus remained high, 
whereas the scores for Zyplast® nearly returned to baseline 
over the period of  24 weeks. At 24 weeks, the mean improve-
ment was still 1.7 with the Juvéderm™ Ultra Plus product 
but only 0.5 with bovine collagen. Longevity was shown by 
maintenance of the clinical correction for 1 year or more in 
81% of NLFs treated with Juvéderm™. The median volume of 
Juvéderm™ required was 0.7 mL (one syringe), signiﬁ  cantly 
less than for Zyplast® (1.6 mL). For the initial treatment, 
the median volume of Juvéderm™ Ultra Plus injected was 
2 syringes (1.6 mL), and less than 1 syringe (0.7 mL) for the 
retreatment at after 6–9 months.
Treatment site reactions were similar for Juvéderm™ Ultra 
Plus and Zyplast® and were similar to those in the above-
mentioned trials. As for patient satisfaction, most subjects 
preferred Juvéderm™ Ultra Plus (85%) versus collagen 
(10%); 5% showed no preference.Clinical Interventions in Aging 2008:3(4) 634
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In summary, all three studies above show superior longevity 
of the HA Juvéderm™ ﬁ  llers compared to bovine collagen 
ﬁ  llers. Juvéderm™ Ultra Plus was shown to exert longer lasting 
clinical results than Juvéderm™ Ultra. Initial treatments required 
roughly two syringes of Juvéderm™, and retreatments required 
only one syringe. Volumes required for collagen were higher 
throughout the studies. Treatment site reactions and side effects 
were similar for all ﬁ  llers, HA and collagen, and were always 
short in duration (less than 7 days) and mild in severity. Most 
patients seem to prefer Juvéderm™ ﬁ  llers to bovine collagen.
Juvéderm™ Ultra Plus was compared with Radiesse® in an 
European study by Moers-Capri et al (2007) that compared the 
hydroxylapatite ﬁ  ller with two HA ﬁ  llers for the treatment of 
the nasolabial folds. The objective of this multicenter, blinded, 
randomized trial was to compare patient satisfaction, efﬁ  cacy 
and durability of the various ﬁ  llers. A total of 205 patients 
were randomized into 3 arms, receiving Radiesse® (CaHA 
gel), Juvéderm™ Ultra, or Perlane®. After the ﬁ  rst treatment 
a touch-up was performed 4 months later and patients were 
followed up at 8, and 12 months, without any additional touch-
ups. The injections were performed with a 27-gauge needle 
into the mid to deep dermis. At 8 months follow-up, NLFs 
treated with CaHA gel were signiﬁ  cantly more improved, than 
with any HA, as assessed by Global Aesthetic Improvement 
Scale (GAIS) (Narins et al 2003). Moreover, the volumes 
used for CaHA gel were lower than for the HAs. In the patient 
satisfaction CaHA consistently scored highest, and Juvéderm™ 
scored lowest, even lower than Perlane®.
There are many factors to be understood, in order to know 
which HA ﬁ  ller to use (Table 3). Because no peer-reviewed 
scientiﬁ  c publications have reviewed the above-mentioned 
properties, it is impossible at this point to know how 
important these various characteristics are in choosing a 
ﬁ  ller. More data need to be collected to properly understand 
if, for example, sizing technology makes a difference or if 
ester bonds last longer than ether bonds. These distinctions 
will become clearer and more important as more HA ﬁ  llers 
reach the market and more data are collected.
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